SUPN - צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים supernus.com

Supernus Pharmaceuticals (SUPN) is driving profit growth through a strategy of replenishing its pipeline with niche molecules and R&D, as evidenced by the quarterly EPS growth rate. The 245.00 mark records this metric. Revenues are based on sales of Qelbree and Trokendi XR, while high margins are sustained by unique extended-release drug technologies. The quarterly EPS growth rate clearly demonstrates the business's reaction to market changes.
supernus.com (SUPN) - פילוחי מדדים ודוחות פיננסיים

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric allows an investor to assess the business scaling rate and its operational efficiency. By analyzing relative quarterly EPS dynamics, one can identify the trend's resilience to fundamental factors. For Supernus Pharmaceuticals (SUPN), this indicator reflects the impact of the patent cycle and the success of new CNS drugs. A positive vector here confirms the stability of the market positions of key medications.